Cases started on MDR-TB treatment in Kazakhstan
Kazakhstan: Cases started on MDR-TB treatment was 4,641 in 2024. ▼ Falling
Cases started on MDR-TB treatment in Kazakhstan, 2009–2024
Source: World Health Organization, Global Health Observatory.
Analysis
Kazakhstan recorded 4,641 for cases started on mdr-tb treatment in 2024.
That represents a change of up 4.1% on the previous year and down 36.6% over ten years.
Over the whole period, cases started on mdr-tb treatment in Kazakhstan peaked at 7,315 in 2014 and was at its lowest, 3,209, in 2009.
That places Kazakhstan 7th out of 193 countries with data for 2024, putting it in the top 10%.
The long-run direction has been consistently falling across the 16 years of available data.
Cases started on MDR-TB treatment in Kazakhstan, year by year
| Year | Value | Change |
|---|---|---|
| 2009 | 3,209 | — |
| 2010 | 5,705 | +77.8% |
| 2011 | 5,261 | -7.8% |
| 2012 | 7,213 | +37.1% |
| 2013 | 6,776 | -6.1% |
| 2014 | 7,315 | +8.0% |
| 2015 | 6,948 | -5.0% |
| 2016 | 6,260 | -9.9% |
| 2017 | 5,840 | -6.7% |
| 2018 | 4,814 | -17.6% |
| 2019 | 6,144 | +27.6% |
| 2020 | 5,256 | -14.5% |
| 2021 | 4,654 | -11.5% |
| 2022 | 4,316 | -7.3% |
| 2023 | 4,457 | +3.3% |
| 2024 | 4,641 | +4.1% |
Kazakhstan compared with similar countries
- Kazakhstan's 4,641 is above the median for upper middle income countries, which is 40, 116.0× the median. (57 countries reporting)
- Kazakhstan's 4,641 is above the median for Europe & Central Asia, which is 12.5, 371.3× the median. (48 countries reporting)
Biggest year-on-year movements
Years where Cases started on MDR-TB treatment in Kazakhstan changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2010 | +77.8% | 3,209 | 5,705 |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3,209 | 3,209 | 3,209 | 1 |
| 2010s | 6,228 | 4,814 | 7,315 | 10 |
| 2020s | 4,665 | 4,316 | 5,256 | 5 |
Countries ranked near Kazakhstan
More health data for Kazakhstan
- Un projection of annual infant deaths, annual growth rate -1.35 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.3158 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 825.8 deaths per 1,000 people (2090)
- Number of infants who die before age 1 660 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -1.58 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0485 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.16 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is cases started on mdr-tb treatment in Kazakhstan?
- Cases started on mdr-tb treatment in Kazakhstan was 4,641 in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest cases started on mdr-tb treatment recorded in Kazakhstan?
- The highest recorded value was 7,315 in 2014.
- What is the lowest cases started on mdr-tb treatment recorded in Kazakhstan?
- The lowest recorded value was 3,209 in 2009.
- How does Kazakhstan rank for cases started on mdr-tb treatment?
- Kazakhstan ranks 7th out of 193 countries with data for 2024.
- Is cases started on mdr-tb treatment rising or falling in Kazakhstan?
- Over the last ten years it is down 36.6%. The long-run trend across the full record is falling.
- Where does this Kazakhstan data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Cases started on MDR-TB treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 16 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).